ImmunityBio Stock Rises on Macau Approval for Anktiva Bladder Cancer Drug

ImmunityBio shares gained after Macau approved its drug Anktiva for bladder cancer, its first Asian authorization, supporting global expansion amid a growing immunotherapy market.Read More